| 產(chǎn)品編號 | BIO0079SM |
| 英文名稱 | Anti-human VEGF (Bevacizumab Biosimilar) |
| 中文名稱 | |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 146.5 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG1 |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Bevacizumab inhibited the tumor growth of COLO205 on balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 42.0% at 0.95 mpk at D31.
Immobilized human VEGF165 His at 2 ug/mL can bind Anti-VEGF Reference Antibody (BioMab patent anti-VEGF), EC50=0.003018 ug/mL.
The purity of Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) is 97.8%, determined by SEC-HPLC.
Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
